Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report

Chai, Peiwei; Zhou, Chuandi; Jia, Renbing; Wang, Yefei

doi:10.1186/s13000-019-0922-1

Cited by 8 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, two patients with orbital NUT carcinoma, who had undergone operation, received anlotinib in third-line. The OS was beyond 15 months and 8 months, respectively ( 103 , 104 ).…”

Section: Targeting the Tumor Microenvironmentmentioning

confidence: 99%

Immunotherapy and Targeting the Tumor Microenvironment: Current Place and New Insights in Primary Pulmonary NUT Carcinoma

Shi

Zhang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Primary pulmonary nuclear protein of testis carcinoma is a rare and highly aggressive malignant tumor. It accounts for approximately 0.22% of primary thoracic tumors and is little known, so it is often misdiagnosed as pulmonary squamous cell carcinoma. No effective treatment has been formed yet, and the prognosis is extremely poor. This review aims to summarize the etiology, pathogenesis, diagnosis, treatment, and prognosis of primary pulmonary nuclear protein of testis carcinoma in order to better recognize it and discuss the current and innovative strategies to overcome it. With the increasing importance of cancer immunotherapy and tumor microenvironment, the review also discusses whether immunotherapy and targeting the tumor microenvironment can improve the prognosis of primary pulmonary nuclear protein of testis carcinoma and possible treatment strategies. We reviewed and summarized the clinicopathological features of all patients with primary pulmonary nuclear protein of testis carcinoma who received immunotherapy, including initial misdiagnosis, disease stage, immunohistochemical markers related to tumor neovascularization, and biomarkers related to immunotherapy, such as PD-L1 (programmed death-ligand 1) and TMB (tumor mutational burden). In the meanwhile, we summarized and analyzed the progression-free survival (PFS) and the overall survival (OS) of patients with primary pulmonary nuclear protein of testis carcinoma treated with PD-1 (programmed cell death protein 1)/PD-L1 inhibitors and explored potential population that may benefit from immunotherapy. To the best of our knowledge, this is the first review on the exploration of the tumor microenvironment and immunotherapy effectiveness in primary pulmonary nuclear protein of testis carcinoma.

show abstract

“…In addition, two patients with orbital NUT carcinoma, who had undergone operation, received anlotinib in third-line. The OS was beyond 15 months and 8 months, respectively ( 103 , 104 ).…”

Section: Targeting the Tumor Microenvironmentmentioning

confidence: 99%

Immunotherapy and Targeting the Tumor Microenvironment: Current Place and New Insights in Primary Pulmonary NUT Carcinoma

Shi

Zhang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…A study by Wang et al indicated that stereotactic radiosurgery (SRS) combined with anlotinib limited brain metastases with perilesional edema in NSCLC [ 20 ]. A recent study has reported that radiotherapy combined with anlotinib to treat with orbital NMC [ 21 ]. In this report, we for the first time used palliative radiotherapy combined with anlotinib could significantly alleviate primary lesion of NMC progression, which may provide a way to treat primary pulmonary NMC.…”

Section: Discussionmentioning

confidence: 99%

NUT midline carcinoma as a primary lung tumor treated with anlotinib combined with palliative radiotherapy: a case report

Jiang

Ren

et al. 2022

Diagn Pathol

View full text Add to dashboard Cite

Background NUT (nuclear protein in testis) midline carcinoma (NMC) is a rapidly progressive tumor arising from midline structures. Recent cases have reported that the poor prognosis with a median survival of 6.7 months and a 2 years overall survival of 19% due to limited treatment. Based on the effect of arotinib on inhibiting tumor growth and angiogenesis. We present one patient case treated with anlotinib and radiotherapy. Case presentation Here, we describe a 33-year old patient who complained of cough and chest pain and was diagnosed as a pulmonary NMC through CT scan, FISH and immunohistochemistry. In addition, we initially demonstrated that anlotinib combined with palliative radiotherapy could significantly prevent the tumor growth in a pulmonary NMC. Conclusion The report indicated that anlotinib combined with palliative radiotherapy could inhibit the tumor progression in a pulmonary NMC, which may provide a combined therapy to pulmonary NMC in the future.

show abstract

“…Shi et al have suggested that combination therapy with anlotinib and chemoradiotherapy may be an effective regimen for the treatment of advanced esophageal squamous cell carcinoma (ESCC) [16]. A study by Wang et al indicated that stereotactic radiosurgery (SRS) combined with anlotinib limited brain metastases with perilesional edema in NSCLC [17]. A recent study has reported that radiotherapy combined with anlotinib to treat with orbital NMC [18].…”

Section: Discussionmentioning

confidence: 99%

NUT Midline Carcinoma as a Primary Lung Tumor Treated With Anlotinib Combined With Palliative Radiotherapy: a Case Report

Jen¹,

Ren²,

Xu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: NUT (nuclear protein in testis) midline carcinoma (NMC) is a rapidly progressive tumor arising from midline structures. Recent cases have reported that the poor prognosis with a median survival of 6.7 months and a 2 years overall survival of 19% due to limited treatment. Based on the effect of arotinib on inhibiting tumor growth and angiogenesis. We present one patient case treated with anlotinib and radiotherapy.Case presentation: Here, we describe a 33-year old patient who complained of cough and chest pain and was diagnosed as a pulmonary NMC through CT scan, FISH and immunohistochemistry. In addition, we initially demonstrated that anlotinib combined with palliative radiotherapy could significantly prevent the tumor growth in a pulmonary NMC.Conclusion: The report indicated that anlotinib combined with palliative radiotherapy could inhibit the tumor progression in a pulmonary NMC, which may provide a combined therapy to pulmonary NMC in the future.

show abstract

Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report

Cited by 8 publications

References 16 publications

Immunotherapy and Targeting the Tumor Microenvironment: Current Place and New Insights in Primary Pulmonary NUT Carcinoma

Immunotherapy and Targeting the Tumor Microenvironment: Current Place and New Insights in Primary Pulmonary NUT Carcinoma

NUT midline carcinoma as a primary lung tumor treated with anlotinib combined with palliative radiotherapy: a case report

NUT Midline Carcinoma as a Primary Lung Tumor Treated With Anlotinib Combined With Palliative Radiotherapy: a Case Report

Contact Info

Product

Resources

About